Tyra Biosciences, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $19.61
- 52-Week Range
- $16.86 – $40.65
- Market Cap
- $1.36B
- P/E (TTM)
- —
- EPS (TTM)
- -2.63
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.96
- PEG Ratio
- —
- Return on Equity
- -34.89%
- Return on Assets
- -22.15%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 23.93
- Debt/Equity
- 0.01
- Total Debt
- $5.46M
- Free Cash Flow
- $-66.89M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $667.92M
Market Snapshot
About
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptors (FGFRs). The company is advancing a pipeline of selective FGFR inhibitors designed to treat patients with cancer and other serious diseases. Tyra utilizes its proprietary SNÃ…P platform to design highly selective kinase inhibitors.